Primary afferent second messenger cascades interact with specific integrin subunits in producing inflammatory hyperalgesia.
We recently reported that hyperalgesia induced by the inflammatory mediator prostaglandin E(2) (PGE(2)) requires intact alpha1, alpha3 and beta1 integrin subunit function, whereas epinephrine-induced hyperalgesia depends on alpha5 and beta1. PGE(2)-induced hyperalgesia is mediated by protein kinase A (PKA), while epinephrine-induced hyperalgesia is mediated by a combination of PKA, protein kinase Cepsilon (PKCepsilon) and mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK). We hypothesized that inflammatory mediator-induced hyperalgesia involves specific interactions between different subsets of integrin subunits and particular second messenger species. In the present study, function-blocking anti-integrin antibodies and antisense oligodeoxynucleotides were used to elucidate these interactions in rat. Hyperalgesia produced by an activator of adenylate cyclase (forskolin) depended on alpha1, alpha3 and beta1 integrins. However, hyperalgesia induced by activation of the cascade at a point farther downstream (by cAMP analog or PKA catalytic subunit) was independent of any integrins tested. In contrast, hyperalgesia induced by a specific PKCepsilon agonist depended only on alpha5 and beta1 integrins. Hyperalgesia induced by agonism of MAPK/ERK depended on all four integrin subunits tested (alpha1, alpha3, alpha5 and beta1). Finally, disruption of lipid rafts antagonized hyperalgesia induced by PGE(2) and by forskolin, but not that induced by epinephrine. Furthermore, alpha1 integrin, but not alpha5, was present in detergent-resistant membrane fractions (which retain lipid raft components). These observations suggest that integrins play a critical role in inflammatory pain by interacting with components of second messenger cascades that mediate inflammatory hyperalgesia, and that such interaction with the PGE(2)-activated pathway may be organized by lipid rafts.
Dina
Olayinka A
OA
Department of Medicine, Division of Neuroscience and Biomedical Sciences Program, NIH Pain Center (UCSF), University of California at San Francisco, Campus Box 0440, Room C-555 521, San Francisco, CA 94143-0440, USA.
Hucho
Tim
T
Yeh
Jenny
J
Malik-Hall
Misbah
M
Reichling
David B
DB
Levine
Jon D
JD
D000818:Animals; D005576:Colforsin; D015232:Dinoprostone; D004837:Epinephrine; D005727:Ganglia, Spinal / Q000187:drug effects / Q000378:metabolism*; D006930:Hyperalgesia / Q000139:chemically induced / Q000209:etiology / Q000378:metabolism*; D007249:Inflammation / Q000139:chemically induced / Q000209:etiology / Q000378:metabolism*; D016023:Integrins / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction
D016023:Integrins; D005576:Colforsin; D015232:Dinoprostone; D004837:Epinephrine